G1 Therapeutics Inc logo

GTHX

G1 Therapeutics Inc

$12.23

Earnings Summary

Revenue
$10.57Mn
Net Profits
$-39.45Mn
Net Profit Margins
-373.08%

Highlights

Revenue:

G1 Therapeutics Inc’s revenue jumped 60.1% since last year same period to $10.57Mn in the Q2 2022. On a quarterly growth basis, G1 Therapeutics Inc has generated 53.19% jump in its revenue since last 3-months.

Net Profits:

G1 Therapeutics Inc’s net profit fell -0.06% since last year same period to $-39.45Mn in the Q2 2022. On a quarterly growth basis, G1 Therapeutics Inc has generated 19.81% jump in its net profits since last 3-months.

Net Profit Margins:

G1 Therapeutics Inc’s net profit margin jumped 37.5% since last year same period to -373.08% in the Q2 2022. On a quarterly growth basis, G1 Therapeutics Inc has generated 47.65% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the G1 Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.02
EPS Estimate Current Year
-1.02

Highlights

EPS Estimate Current Quarter:

G1 Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.02 - a -5.15% fall from last quarter’s estimates.

EPS Estimate Current Year:

G1 Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.02.

Key Ratios

Key ratios of the G1 Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.92
Return on Assets (ROA)
-0.44
Return on Equity (ROE)
-1.22
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

G1 Therapeutics Inc’s earning per share (EPS) jumped 1.74% since last year same period to -0.92 in the Q2 2022. This indicates that the G1 Therapeutics Inc has generated 1.74% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. G1 Therapeutics Inc’s return on assets (ROA) stands at -0.44.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. G1 Therapeutics Inc’s return on equity (ROE) stands at -1.22.

Dividend Per Share (DPS):

G1 Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-03
-1.02
-0.92
9.45%
2022-05-04
-0.97
-1.15
-18.56%

Company Information

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.

Organisation
G1 Therapeutics Inc
Headquarters
Research Triangle Park, North Carolina, US
Employees
122
Industry
Health Technology
CEO
Mark Velleca